Shineco Stock Price, News & Analysis

Shineco (NASDAQ: SISI) has achieved a major breakthrough in phospholipid production through its subsidiary Fuzhou Meidashan Biotechnology. The company's proprietary APCC-UF pure physical extraction technology enables large-scale production of high-purity, highly active free-form soybean phospholipids.

The technology delivers impressive metrics: 97.8% total phospholipid content, 50.2% phosphatidylcholine (PC) content, and further purification can achieve ≥99% phospholipid purity and ≥90% PC content. The company has validated production at a thousand-ton scale, with plans to expand to ten-thousand-ton capacity, breaking the foreign monopoly in high-purity phospholipids production.

This breakthrough positions Shineco to compete in pharmaceutical intermediates, mRNA vaccine materials, and high-end skincare markets, with the global pharmaceutical phospholipid market projected to grow at a CAGR of over 15% in the next five years.

Shineco (NASDAQ: SISI) has formed a strategic partnership with Singapore-based BICC Pte Ltd to advance their blockchain-based cell asset ecosystem. The collaboration focuses on implementing and redeeming "on-chain cell assets" across multiple institutions, marking a transition from technical integration to real-world applications.

The partnership builds on Shineco's previous initiatives, including establishing a Cell Digital Division and acquiring a 51% stake in Xi'an Dong'ao Health Management. Plus Me will provide digital management for Shineco's stem cells on Ethereum, while BICC will integrate its iPSC stem cell storage services into Shineco's blockchain system. The collaboration leverages BICC's network of 3,000+ sales representatives and their expertise in wound-healing solutions, cell banking, and exosome delivery technology.

Shineco (NASDAQ: SISI) has announced a groundbreaking partnership with Plus Me Limited to launch the world's first blockchain-based cell asset tokenization platform. The initiative includes the creation of "Cell Infusion Redemption Tokens" on the Ethereum mainnet, enabling digital custody and trading of biological cellular assets.

The company has also acquired a 51% controlling stake in Xi'an Dong'ao Health Management Co., Ltd., strengthening its global storage and infusion network. This strategic acquisition, combined with its existing Singapore-based Infiniclone operations, establishes a comprehensive infrastructure for token redemption and asset settlement.

The platform will utilize ERC-1400/ERC-20 compliant security tokens, with smart contracts ensuring asset ownership rights and regulatory compliance through non-fungible digital identifiers (NFDIs). The ecosystem aims to transform traditional biotech marketing while addressing industry challenges such as high costs and illiquid asset pools.

Shineco (NASDAQ: SISI), an iPSC technology platform manufacturer, has announced the creation of a new Biological Cell Digital Business Division to merge biological cell assets with blockchain technology. The company has appointed Mr. Lin Hongguang, former Chief Researcher at Korea Digital Currency Research Institute, as General Manager of the division.

The division aims to establish a blockchain-based ecosystem for biological cell assets management, focusing on standardized management, IPSC cell bank development, and blockchain-linking. Key objectives include improving cell asset traceability, developing equity transfer mechanisms, and enhancing global distribution efficiency of biological cell products.

The initiative seeks to enable medical institutions to allocate resources more efficiently, implement flexible payment systems, and integrate AI tools to optimize service delivery, making cell technology more accessible globally.

Shineco (Nasdaq:SISI) has announced a 50:1 reverse stock split of its common stock, effective August 11, 2025. The measure aims to comply with Nasdaq's minimum bid price requirement for continued listing. The split will reduce outstanding shares from approximately 45,722,728 to 914,455.

The company's stock will continue trading under the symbol "SISI" with a new CUSIP number (824567606). The split follows stockholder approval on July 3, 2025, which authorized a ratio between 25:1 and 60:1. Proportionate adjustments will be made to exercise prices and shares underlying equity awards. Stockholders holding shares in book-entry form need not take action, while those holding certificates will receive instructions from Transhare, the transfer agent.

["Potential compliance with Nasdaq minimum bid price requirement", "Stockholder-approved corporate action to maintain listing status", "Automatic rounding up of fractional shares benefits shareholders"]

Shineco (NASDAQ: SISI) announced that CEO Jennifer Zhan and CFO Sam Wang will initiate a stock purchase program to buy up to $2 million worth of company shares at a maximum price of $1.50 per share. The executives will use their personal funds to make open-market purchases, demonstrating their confidence in the company's undervalued stock price. The timing and volume of purchases will be determined by various factors, including general business conditions and stock pricing. CEO Zhan emphasized that this insider-led initiative reflects management's strong belief in Shineco's long-term growth potential, technological advantages, and market opportunities in the innovative medical diagnostics sector.

Shineco (NASDAQ: SISI) announced that its subsidiary InfiniClone, in which it holds a 51% stake, has entered into a strategic distribution agreement with Total World Marketing (TWM) to expand into Southeast Asia's healthcare market. InfiniClone will offer two main product lines: molecular detection kits based on iPSC technology for analyzing genetic mutations and diseases, and Purelix health products for customized immune enhancement and health solutions. TWM has begun pilot sales of Purelix products in Thai supermarkets and plans to expand to pharmacies, clinics, and e-commerce platforms once FDA approval is obtained for the molecular detection kits. The Southeast Asian healthcare market shows strong growth potential, with e-commerce platforms Shopee and Lazada reporting $1.57 billion in healthcare product sales in 2023, marking a 25% year-over-year increase.

Shineco (NASDAQ: SISI) has announced the acquisition of a 51% stake in InfiniClone , a Hong Kong-based biotechnology company specializing in regenerative medicine and stem cell technology. The transaction, valued at $19,895,600 in cash plus 3,450,000 shares of Shineco common stock, was executed through Shineco's subsidiary, Shineco Life Sciences.

InfiniClone possesses 29 global patents across major markets including the US, Europe, and Asia. Their innovative technology claims to increase cell expansion throughput by 3-10x compared to existing methods and reduce production costs by over 60%. The company's proprietary methods could potentially reduce treatment preparation time for conditions like Parkinson's, Alzheimer's, and stroke from months to weeks.

The acquisition marks Shineco's strategic entry into stem cell technology and regenerative medicine, with the company aiming to accelerate InfiniClone's technology transition from laboratory to clinical applications.

Shineco (NASDAQ: SISI) has announced the acquisition of a 75% equity stake in FuWang Company, a specialist in medical device R&D, manufacturing, and commercialization. The deal, signed on March 20, 2025, involves a payment of US$8.8 million in cash, issuance of 3,400,000 Shineco common shares, and transfer of 71.42% equity in Dream Partner

FuWang Company develops Class II and III medical devices, including biochemical analyzers, patient monitors, and mobile medical imaging workstations. The company has a strong market presence across Chinese provinces, particularly in Gansu, Henan, Jiangsu, and Shanxi.

The acquisition target projects revenue growth from US$11.03 million in 2025 to US$17.24 million by 2027, with net profit expectations ranging from US$1.10 million to US$1.72 million during the same period. FuWang plans to expand into integrated health management, leveraging cloud computing and AI technologies for critical care networks.